Suddenly, cannabis-related, hemp-derived CBD is almost everywhere. CBD’s FDA status is murky, and we know very little about its benefits, thanks in part to its former place on DEA Schedule 1. How much has been proven about its supposed health qualities? What are the risks? Experts discuss in depth.
Guests:
Joanne, Florida RN and CBD user Dr. Yasmin Hurd, Director, Addiction Institute, Icahn School of Medicine at Mount Sinai, New York Don Ballou, founder and CEO, CBD Essence Products Dr. Tim Welty, Director, Research, Innovation and International Programs, College of Pharmacy and Health Sciences, Drake UniversityLinks for more information:
Yasmin Hurd, PhD – Icahn School of Medicine at Mount Sinai Learn more about CBD Essence Timothy E Welty, PharmD – The Conversation
Create your
podcast in
minutes
It is Free